Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report)’s share price traded down 3.5% during trading on Friday . The stock traded as low as $16.14 and last traded at $16.50. 11,425 shares changed hands during trading, a decline of 95% from the average session volume of 208,577 shares. The stock had previously closed at $17.10.
Wall Street Analyst Weigh In
Several analysts recently commented on SION shares. TD Cowen started coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a “buy” rating on the stock. Guggenheim started coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They set a “buy” rating and a $32.00 target price for the company.
Sionna Therapeutics Price Performance
Sionna Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Further Reading
- Five stocks we like better than Sionna Therapeutics
- What Does Downgrade Mean in Investing?
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- What Is WallStreetBets and What Stocks Are They Targeting?
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- 10 Best Airline Stocks to Buy
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
